Analysis originally distributed on June 7, 2017 By: Michael Vodicka of Cannabis Stock Trades
Blockbuster drugs are the holy grail of the pharmaceutical and biotech industry.
When annual sales of a new drug break the $1 billion mark, investors are usually rewarded with big gains.
This is what began happening late 2012 with Gilead Science (NASDAQ:GILD).
In 2013 the FDA approved Gilead's hepatitis C drug Sovaldi.
Then, in 2014, Gilead scored an FDA approval for another Hep C drug, Harvoni.
Both drugs went on to quickly hit blockbuster status - sending shares of Gilead soaring - jumping more than 200% in the next two years. Take a look below.
Image courtesy of MarketClub.com
Today, the young cannabis industry is in hot pursuit of its first ever cannabis blockbuster - and I expect the winner of this race to deliver huge gains to shareholders. Continue reading "A 2nd Cannabis Stock With $1 Billion Drug Potential"
Analysis originally distributed on June 1, 2017 By: Michael Vodicka of Cannabis Stock Trades
Amazon was at the top of the headlines this week after its share price broke $1,000.
Amazon is now up 1,300% in the last 10 years. That is a nice win for shareholders. Early investors are sitting on big gains.
It’s also a reminder of where consumers are spending their money these days – online.
Any business that wants to thrive has to be winning online.
This is true in the cannabis industry. Just like the broader retail industry – online cannabis sales are booming.
However, Canada’s young cannabis companies are struggling to meet that growing demand.
To get the latest analysis as soon as it is released, please subscribe to our free weekly newsletter.
They are still being hampered by burdensome banking restrictions.
For example, Canadian cannabis producers have been banned from using PayPal because the U.S. based company is subject to US federal restriction on cannabis.
Even some larger banks have declined to provide financial service to Canada’s cannabis industry simply because its so new and considered higher risk. Continue reading "Will This Micro Cap Be The PayPal Of Canada's Cannabis Industry?"
Analysis originally distributed on May 24, 2017 By: Michael Vodicka of Cannabis Stock Trades
Investing in cannabis IPOs for the last few years has been extremely profitable.
Take Aphria Inc. (APHFQ), one of Canada's largest medical cannabis companies, for example.
Shares began trading on the Toronto Stock Exchange in October of 2015.
Now, just 18 months later, Aphria is up 499%. Take a look below.
Shares did get off to a slow start. And from there it wasn't a straight shot higher.
But as you can see, investors who bought early in the game are sitting on the biggest gains. And looking forward, early investors will still be collecting the biggest profits because they have the lowest cost basis.
If you're interested in profiting from future cannabis IPOs, you're in luck. Continue reading "Another 499% Gain In 18 Months On Tap?"
Analysis originally distributed on May 19, 2017 By: Michael Vodicka of Cannabis Stock Trades
First-quarter earnings season is almost over.
And the cannabis sector has been knocking it out of the park.
A lot of the stocks that we have covered over the last few months have stepped up and delivered excellent results.
Let's take a closer look.
In terms of pure growth, the best report I've seen came from Aurora Cannabis (ACBFF), one of the largest medical cannabis companies in Canada
Revenue jumped 2,500% from the same period last year to $5.2 million and was up 33% from just last quarter. Continue reading "Aurora Delivers 2,500% Revenue Growth in 12 Months"
Analysis originally distributed on April 26, 2017 By: Michael Vodicka of Cannabis Stock Trades
Israel has long been a powerhouse in medical innovation.
The tiny country of 8.5 million has made some of the most important contributions to the global medical field in the last 50 years.
Today, Israel is unleashing its innovative medical industry on the cannabis industry.
According to a report from Reuters, there are more than 120 clinical cannabis trials in Israel at the beginning of 2017, more than any other country.
Foreign countries and firms are eager to license Israel cannabis medical patents. In the last year outside countries and companies have invested $100 million to license Israeli medical cannabis patents.
That number is expected to grow to more than $1 billion in the next two years - an increase of 1,000%.
Israel is winning in the global cannabis industry for two reasons. Continue reading "This Little-Known Israeli Biotech Is Up 468% In 2017"